Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 + tislelizumab ± chemotherapy in gastric/GEJ adenocarcinoma
NCT04363801Phase 2Terminated
- Sponsor
- Leap Therapeutics, Inc.
- Start
- Jul 2020
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of sirexatamab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Leap Therapeutics, Inc.. Started Jul 2020; status: terminated.
02
Drugs
sirexatamab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04363801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04363801.